Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussion in Yahoo Finance's forum. Statement of changes in beneficial ownership of securities, Automatic shelf registration statement of securities of well-known seasoned issuers, Annual report [Section 13 and 15(d), not S-K Item 405], Chief Executive Officer, President and Director, Senior Vice President and Chief Operating Officer, Senior Vice President, Chief Legal Officer and Secretary, Senior Vice President and Chief Commercial Officer, Senior Vice President, Chief Financial Officer and Treasurer, Senior Vice President, Chief Accounting Officer and Principal Accounting Officer. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. Their average twelve-month price target is $9.63, predicting that the stock has a possible upside of 158.74%. The biotech reported great news for its lead pipeline candidate. CAMBRIDGE, Mass., Sept. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 4.35% and 18.24%, respectively, for the quarter ended June 2020. The Akebia Therapeutics stock price fell by -2.20% on the last day (Monday, 8th Mar 2021) from $3.41 to $3.33. Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis. Akebia Therapeutics is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Akebia Therapeutics, Inc. (AKBA) Stock Price: $3.72 USD 0.20 (5.68%) Updated Mar 11, 2021 4:00 PM EST - Market closed. The price has fallen in 6 of the last 10 days and is down by -18.98% for this period. Investors can use this forecasting interface to forecast Akebia Therapeutics historical stock prices and determine the direction of Akebia Therapeutics's future trends based on various well-known forecasting models. See Akebia Therapeutics, Inc. (AKBA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Akebia Therapeutics Inc. AKBA. View Akebia Therapeutics, Inc. AKBA investment & stock information. Stock Price Statistics The stock price has decreased by -61.01% in the last 52 weeks. Albemarle trades on the New York Stock Exchange (NYSE) under the ticker symbol \"ALB.\" Albemarle declared a quarterly dividend on Wednesday, May 8th. Akebia Therapeutics Inc. [NASDAQ: AKBA] traded at a high on 01/27/21, posting a 1.35 gain after which it closed the day’ session at $3.76. Akebia Therapeutics, Inc. (AKBA) Stock Price: $3.43 USD 0.03 (0.73%) Updated Mar 8, 2021 12:22 PM EST - Market open. According to 8 analysts, the average rating for AKBA stock is "Buy." The market cap for the stock reached $426.40 million, with 143.32 million shares outstanding and 139.94 million shares in … According to 8 analysts, the average rating for AKBA stock is "Buy." Financial ratios and metrics for Akebia Therapeutics stock (AKBA). Stable Share Price: AKBA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 13% a week. The company report on January 6, 2021 that Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference. Shares down. Do the numbers hold clues to what lies ahead for the stock? CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno... CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 ... CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann... CAMBRIDGE, Mass., Nov. 16, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann... Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately. Akebia Therapeutics, Inc. Common Stock (AKBA) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets. CAMBRIDGE, Mass., March 11, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, celebrat... With the trading day about halfway over, the broad markets were pushing higher on the day. Volatility Over Time: AKBA's weekly volatility (13%) has been stable over the past year. Get prepared with the key expectations. Technical Analysis for AKBA - Akebia Therapeutics, Inc. Quote; Chart; End-of-Day Signals; Intraday Alerts; Profile; Buy or Sell? The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. The high price target for AKBA is $18.00 and the low price target for AKBA is $3.00. During the day the stock fluctuated 7.29% from a day low at $3.29 to a day high of $3.53. CAMBRIDGE, Mass., Oct. 9, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that it will present data from its global Phase 3 programs of vadadustat for the treatment of ane... Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. AKBA Profile. Akebia Therapeutics, Inc. has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2020 Results - Earnings Call Transcript. Shareholders of record on Friday, June 14th will be paid a dividend of $0.3675 per share on Monday, July 1st. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Our Ai stock analyst implies that there will be a negative trend in the future and the AKBA shares are not a good investment for making money. AKBA Stock Analysis Overview What this means: InvestorsObserver gives Akebia Therapeutics (AKBA) an overall rank of 44, which is below average. AKBA Stock Performance Analysis: Akebia Therapeutics Inc. [AKBA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.01. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in … Shares of Akebia Therapeutics Inc. gained 30% in premarket trading on Tuesday after the drugmaker reported positive topline results from a Phase 3 trial for patients with chronic kidney disease. CAMBRIDGE, Mass., Aug. 10, 2020 /PRNewswire/ -- Top-line data readout of global Phase 3 PRO2TECT program of vadadustat for treatment of anemia due to CKD in adult patients not on dialysis on track for e... CAMBRIDGE, Mass., Aug. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. CAMBRIDGE, Mass., June 29, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an... CAMBRIDGE, Mass., June 18, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today... Is (AKBA) Outperforming Other Medical Stocks This Year? Overview. AKBA -- USA Stock : USD 3.59 0.26 7.81% : Akebia Therapeutics Stock Forecast is based on your current time horizon. Akebia Therapeutics, a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The 12-month stock price forecast is 6.71, which is an increase of 80.38% from the latest price. Share your opinion and gain insight from other stock traders and investors. After-hours: $3.76 +0.04 (1.08%) Mar 11, 7:59 PM. Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appo... CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 19... With the trading day practically over, the broad markets were sliding into the weekend. Follow along and learn as I perform a quick stock chart technical analysis review on the Akebia Therapeutics, Inc. (AKBA) chart. View Albemarle's Dividend History. CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 ... CAMBRIDGE, Mass., Oct. 23, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced the presentation of clinical data from its PRO2TECT global Phase 3 program that evaluated the ef... CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced the presentation of clinical data from its global INNO2VATE Phase 3 program, which demonstrated t... Baupost Group leader Seth Klarman (Trades, Portfolio) disclosed earlier this week he divested of his position in Akebia Therapeutics Inc. (NASDAQ:AKBA). … Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). AKBA Stock Performance Analysis: Akebia Therapeutics Inc. [AKBA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.12. As of 2021 March 04, Thursday current price of AKBA stock is 3.365$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception). This represents a $1.47 annualized dividend and a yield of 2.02%. The company report on January 6, 2021 that Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference. Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. CAMBRIDGE, Mass., March 2, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted f... Investors were not impressed with the drugmaker's latest quarterly update. The company's lead pipeline candidate fell short in a late-stage clinical study. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 25.40% and 14.11%, respectively, for the quarter ended March 2020. The 12-month stock price forecast is 6.71, which is an increase of 85.87% from the latest price. View real-time stock prices and stock quotes for a full financial overview. Akebia Therapeutics Inc. [NASDAQ: AKBA] gained 0.96% or 0.03 points to close at $3.17 with a heavy trading volume of 9826247 shares. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and t... [Read more...]. Based on analysts offering 12 month price targets for AKBA in the last 3 months. Resistance Levels /Pt's2.853.003.203.654.255.006.006.507.007.5008.00 Get the hottest stocks to trade every day before the market opens 100% free. The 12-month stock price forecast is 6.71, which is an increase of 80.38% from the latest price. Get the hottest stocks to trade every day before the market opens 100% free. Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. With this latest performance, AKBA shares gained by 8.36% in over the last four-week period, additionally sinking by -74.82% over the last 6 months – not to mention a drop of -54.93% in the past year of trading. Financials. Rating as of Feb 19, 2021. Do the numbers hold clues to what lies ahead for the stock? Get today's Akbar Indomakmur Stimec Tbk stock price and latest AIMS news as well as Akbar Indomakmur real-time stock quotes, technical analysis, full financials and more. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Support Levels/ Loads 2.652.50none under watch out ! CAMBRIDGE, Mass., June 10, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann... CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno... CAMBRIDGE, Mass., May 19, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno... As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA). Get the latest Akebia Therapeutics, Inc. AKBA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The ex-dividend date of this dividend is Thursday, June 13th. Since this share has a negative outlook we recommend looking for other projects instead to build a portfolio. Sector: Health Technology Industry: Biotechnology Employees: 360 Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The beta is 1.89, so AKBA's price volatility has been higher than the market average. Shares of Akebia Therapeutics (NASDAQ:AKBA) surged 24% after the company reported Q1 results. Swing Trading with Technical AnalysisWelcome to my channel! Their pr… In 2020, AKBA's revenue was $295.31 million, a decrease of -11.85% compared to the previous year's $335.00 million. Losses were -$383.46 million, 37.1% more than in 2019. Statistics. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript. On Thursday, Akebia Therapeutics Inc. (NASDAQ: AKBA) announced topline results from the Phase 3 PRO2TECT studies evaluating the safety and efficacy of vadadustat in chronic kidney disease (CKD). The average equity rating for AKBA stock is currently 2.20, trading closer to a bullish pattern in the stock market. Do the numbers hold clues to what lies ahead for the stock? News & Commentary; Indicators; Fundamentals; Grade Last Price % Change Price Change; D: 3.6: 8.11%: 0.27: AKBA closed up 8.11 percent on Tuesday, March 9, 2021, on 64 percent of normal volume. AKBA | Complete Akebia Therapeutics Inc. stock news by MarketWatch. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Overview. Akebia Therapeutics, a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. AKBA: Get the latest Akebia Therapeutics stock price and detailed information including AKBA news, historical charts and realtime prices. Over the last 12 months, AKBA stock dropped by -54.80%. A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. 14 brokerages have issued 12-month price objectives for Albemarle's shares. Learn how to trade big board and penny stocks by learning to read stock charts and identify technical patterns through technical analysis. Includes annual, quarterly and trailing numbers with full history and charts. CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today anno... CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted ei... Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately. AKBA, $AKBA, Akebia Therapeutics Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis indicators Morningstar Rating. Akebia Therapeutics and Satsuma Pharmaceuticals could both be big winners for early shareholders. Akebia Therapeutics, Inc. (AKBA) is vying with several other pharma companies to bring potentially game-changing treatments for kidney dialysis patients.
Tbi Medical Meaning, Black Mirror Font, Oic Meeting In Pakistan, Blues Vs Highlanders Score, 3d Fm Playlist, Internet Radio Licence Uk, The Weather Channel Northport, Ny, Mcdonald-kreitman Test Khan Academy, Wow Character History,